What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection”In the company’s words, NCT03920007 on ClinicalTrials.gov
- Tested for
- Leber Congenital Amaurosis, LCA, LCA1
- Main trialPhase 1/2
- “Primary Objective: To evaluate the safety and tolerability of ascending doses of ATSN-101 administered as a unilateral subretinal injection in patients with Leber Congenital Amaurosis (LCA) caused by autosomal recessive guanylate cyclase 2D (GUCY2D) mutations (GUCY2D-LCA). Secondary Objective: To evaluate the efficacy of ascending doses of ATSN-101 administered as a unilateral subretinal injection in patients with GUCY2D-LCA.”In the company’s words, NCT03920007 on ClinicalTrials.gov
Other drugs for Leber Congenital Amaurosis
- Voretigene neparvovec-rzylSpark Therapeutics, Inc. · Phase 3
- SepofarsenLaboratoires Thea · Phase 3
- OCU400Ocugen · Phase 1/2
- OPGx-RDH12Opus Genetics, Inc · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 19 May 2023 | Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026